{"id":104005,"date":"2026-06-09T21:14:10","date_gmt":"2026-06-09T21:14:10","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/104005\/"},"modified":"2026-06-09T21:14:10","modified_gmt":"2026-06-09T21:14:10","slug":"assessing-novo-nordisk-cpsenovo-b-valuation-as-share-price-weakness-follows-a-tough-year","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/104005\/","title":{"rendered":"Assessing Novo Nordisk (CPSE:NOVO B) Valuation As Share Price Weakness Follows A Tough Year"},"content":{"rendered":"\n

Track your investments for FREE<\/a> with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.<\/p>\n

Recent performance snapshot <\/p>\n

Novo Nordisk (CPSE:NOVO B) has seen mixed share performance, with the stock down 0.7% over the past day and 2.8% over the past week, but up 8.1% over the past 3 months.<\/p>\n

Over longer periods the picture is more challenging, with the stock down over the past month, year to date, and past year, while still showing a gain over the past 5 years. This provides important context before looking at fundamentals.<\/p>\n

See our latest analysis for Novo Nordisk.<\/a><\/p>\n

At a share price of DKK270.0, Novo Nordisk\u2019s 1 month share price return is down 7%, while its 1 year total shareholder return is down 46%, pointing to fading momentum after a stronger 5 year total shareholder return of 16%.<\/p>\n

If you are comparing Novo Nordisk with other healthcare opportunities, it could be worth scanning for ideas in fast growing healthcare and biotech using the 132 healthcare AI stocks<\/a><\/p>\n

With Novo Nordisk now carrying a DKK270.0 share price after a tough year and some slowing earnings growth, the key question is simple: is this a reset that leaves potential upside on the table, or is the market already pricing in future growth?<\/p>\n

Most Popular Narrative: 33.8% Undervalued <\/p>\n

Against the last close of DKK270.0, the most followed narrative on Novo Nordisk sees a fair value of DKK407.77, implying a sizeable valuation gap that the market has not closed.<\/p>\n

Bottom Line: Novo Nordisk is transitioning from a high-growth momentum stock to a mature dominant player fighting off rivals. It remains a high-quality business, but the days of effortless earnings beats are likely behind us.<\/p>\n

Read the complete narrative.<\/a><\/p>\n

The valuation hinges on how long high margins can be maintained while earnings, revenue and future profit multiples adjust to a slower growth phase and heavier competition.<\/p>\n

Result: Fair Value of DKK407.77 (UNDERVALUED)<\/p>\n

Have a read of the narrative in full and understand what’s behind the forecasts.<\/a><\/p>\n

However, this depends on key risks, including potential margin pressure from lower priced China sales and higher costs tied to oral Wegovy production and capacity.<\/p>\n

Find out about the key risks to this Novo Nordisk narrative.<\/a><\/p>\n

Next Steps <\/p>\n

With sentiment clearly split between risk and reward, it helps to see the full picture quickly and decide where you stand using the 3 key rewards and 3 important warning signs.<\/p>\n

Looking for more investment ideas? <\/p>\n

If you stop with just one stock, you risk missing other opportunities that could fit your goals even better. Keep your watchlist open and active.<\/p>\n","protected":false},"excerpt":{"rendered":"Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million…\n","protected":false},"author":2,"featured_media":104006,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[2236,53041,272,948,1739],"class_list":["post-104005","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-earnings-growth","tag-healthcare-opportunities","tag-novo-nordisk","tag-share-price","tag-total-shareholder-return"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116722222233596291","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/104005","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=104005"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/104005\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/104006"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=104005"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=104005"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=104005"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}